Abstract:Hintergrund Obwohl die Insulinpumpentherapie (CSII) derzeit im Vergleich zur Insulininjektionstherapie eine deutlich physiologischere Methode der Insulinsubstitution darstellt, wenden in Deutschland im Vergleich zu anderen Ländern weniger Menschen mit einem Typ-1-Diabetes diese Therapieform an. Eine Bedeutung könnten hierbei psychologische Faktoren wie Erwartungen und Einstellungen gegenüber einer Insulinpumpentherapie zukommen. In dieser nicht-interventionellen Beobachtungsstudie wurden die Einstellungen zur Insulinpumpentherapie erwachsener Insulinpumpenträger 6 Monate nach Neueinstellung mit Erwachsenen mit einer mehrfachen täglichen Insulininjektionstherapie (MDI) verglichen. Methoden Einstellungen zur CSII-Therapie wurden mit dem Insulin Pump Attitudes Questionnaire (IPA-Q) erfasst, sowohl bei Teilnehmern der YES-Studie, einer nicht-interventionellen Post Market Surveillance Study zur Effektivität und Sicherheit der mylife YpsoPump (ohne Hybrid-Closed-Loop Algorithmus (= CSII-Nutzer), als auch bei MDI-Anwendern der IPA-Q-Evaluierungsstudie. Ergebnisse Es wurden die Fragebogendaten von n=191 Teilnehmern (CSII-Nutzer: n=81 Teilnehmer der YES-Studie; MDI-Nutzer: n=110 Teilnehmer der IPA-Q Evaluierungsstudie) ausgewertet. CSII-Nutzer, die eine mylife YpsoPump verwenden, standen 6 Monate nach der Neueinstellung oder Umstellung auf eine CSII-Therapie einer solchen signifikant positiver gegenüber als Nutzer einer MDI-Therapie, während gleichzeitig weniger Nachteile der Insulinpumpentherapie berichtet wurden. Schlussfolgerungen Diese Studie zeigt eine hohe Relevanz psychologischer Faktoren für die Akzeptanz und Implementierung einer Insulinpumpentherapie. Strukturierte Diabetesschulungen für Menschen mit Typ-1-Diabetes und eine gute technische Einweisung bei Personen, die sich für eine Insulinpumpentherapie entschieden haben, können dazu beitragen, unrealistische Erwartungen und inadäquate negative Einstellungen zur Insulinpumpentherapie abzubauen. Background Although insulin pump therapy (CSII) is currently the most physiological method of insulin delivery compared to insulin injection therapy, fewer people with type 1 diabetes in Germany use this form of therapy compared to other countries. Psychological factors such as expectations and attitudes towards insulin pump therapy could play a role in this respect. In this non-interventional observational study, attitudes of insulin pump users 6 months after starting insulin pump therapy respectively after switching to another insulin pump model were compared with those of people on multiple daily insulin injection (MDI) therapy. Methods Attitudes towards CSII therapy were measured using the Insulin Pump Attitudes Questionnaire (IPA-Q), both in participants of the YES study, a non-interventional post market surveillance study on the effectiveness and safety of the mylife YpsoPump without hybrid-closed-loop algorithm (= CSII users), and in MDI users of the IPA-Q evaluation study. Results The questionnaire data of n=191 participants (CSII users: n=81 participants of the YES study; MDI users: n=110 participants of the IPA-Q evaluation study) were analyzed. CSII users using a mylife YpsoPump were significantly more positive about CSII therapy 6 months after starting or switching to CSII therapy than MDI users, while fewer disadvantages of insulin pump therapy were reported. Conclusions This study demonstrates in particular the high relevance of psychological factors for the acceptance and implementation of insulin pump therapy. Structured diabetes education for people with type 1 diabetes and good technical instruction for people who have opted for insulin pump therapy can help to reduce unrealistic expectations and inadequate negative attitudes towards insulin pump therapy. Received: 19 December 2023 Accepted after revision: 08 February 2024 Article published online: 04 October 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

'For me, it didn't seem as drastic a step as being controlled by insulin': A qualitative investigation of expectations and experiences of non-insulin injectable therapy among adults with type 2 diabetes

Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study

Early type 2 diabetes treatment intensification with glucagon-like peptide-1 receptor agonists in primary care: An Australian perspective on guidelines and the global evidence

Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK

Experiences of adolescents and young adults with type 1 diabetes and chronically elevated glucose levels following the transition from multiple daily injections to advanced hybrid closed‐loop: A qualitative study

"You can hide it if you want to, you can let it be seen if you want to": A qualitative study of the lived experiences of Australian adults with type 1 diabetes using the Omnipod DASH® system

Lived experience of older adults with type 1 diabetes using closed-loop automated insulin delivery in a randomised trial

GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date

Glucagon-like-peptide-1 receptor agonists and the management of type 2 diabetes-backwards and forwards

Type 2 diabetes in the US managed care setting: the burden of disease and rationale for an oral glucagon-like peptide-1 receptor agonist

The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes

A qualitative study of the mental health outcomes in people being treated for obesity and type 2 diabetes with glucagon-like peptide-1 receptor agonists

Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review

Efficacy, adherence and persistence of various glucagon-like peptide-1 agonists: nationwide real-life data

Einstellung zur Insulinpumpentherapie bei Menschen mit Typ-1-Diabetes sechs Monate nach Umstellung im Vergleich zu mehrfach täglichen Insulininjektionen – Eine Beobachtungstudie

Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?

The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia

The Current and Future Role of Insulin Therapy in the Management of Type 2 Diabetes: A Narrative Review

Results of an Australian trial of an automated insulin delivery (AID) system and other studies support likely benefit of AID use for many Australian adults with type 1 diabetes

Real-World Evaluation of GLP-1 Receptor Agonist Therapy Persistence, Adherence and Therapeutic Inertia Among Obese Adults with Type 2 Diabetes

A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes